Ozempic

Healthcare

UnitedHealth Boosts Profit Forecast Without Committing to Medicare Obesity Drug Coverage

Photo via Steven Garcia/ZUMAPRESS/Newscom

The company now expects 2026 adjusted earnings of more than $18.25 per share, a jump from the $17.75 per share it previously forecasted.

2 min read

Photo via Richard B. Levine/Newscom

Consumer

McDonald’s Spices Up Soft Drink Menus with Dirty Sodas, Specialty Bevs

McDonald’s plans to keep prices in its new beverages’ prices lower than competitors like Starbucks and Dutch Bros.

1 min read
Photo via Gado Images/Smith Collection/Gado/Sipa USA/Newscom

Healthcare

GLP-1 Race Heats Up with Positive Test Results for Next-Gen Eli Lilly Drug

Approximately one in eight Americans are taking medications like Ozempic or Wegovy for weight loss, diabetes, heart disease and more.

2 min read
Photo via Michael Siluk/UCG/Universal Images Group/Newscom

Healthcare

Hims Teams up with Novo to Compete for Weight Loss Scripts

The two struck a deal Monday for Hims to offer official versions of Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy.

2 min read

Healthcare

Novo Nordisk Launches Suit to Knock Out Hims & Hers’ Weight Loss Knockoffs

Photo via Ritzau Scanpix/Sipa USA/Newscom

Novo’s Copenhagen-listed shares rose 5.2% on Monday. New York-listed shares in Hims & Hers, meanwhile, shed an Ozempic-like 16% in volume.

2 min read

Healthcare

Novo Nordisk Seeks to Expand Liver Disease Treatments in $5.2B Deal for Bay Area Biotech

Photo via Ritzau Scanpix/Sipa USA/Newscom

The acquisition comes as new CEO Mike Doustdar tries to revive once meteoric growth that has come crashing down to earth this year.

2 min read

Healthcare

Hims & Hers Struggles After the FDA Puts a Ticking Clock on its Weight-Loss Drug

Photo by Chemist4U via CC BY-SA 2.0

Now that semaglutide’s no longer in shortage territory, the FDA said drug-makers have 90 days to wrap up production of their Novo knockoffs.

2 min read

Sign Up for The Daily Upside to Unlock This Article

Sharp news & analysis on finance, economics, and investing.